Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)

PHASE2TerminatedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

May 31, 2008

Conditions
Lung Cancer
Interventions
DRUG

Motexafin Gadolinium

"On Day 1 of each 3 week cycle for up to 12 cycles:~MGd 10 mg/kg infused over approximately 30 to 60 minutes, followed ≥ 30 minutes later by Docetaxel 75 mg/m2 administered IV over approximately 1 hour."

Trial Locations (22)

Unknown

Wilshire Oncology Medical Group, La Verne

University of Rochester, Rochester

Tri-County Hematology & Oncology Associates, Canton

University of Cincinnati, Cincinnati

The Cleveland Clinic Foundation, Cleveland

Pennsylvania Oncology Hematology Associates, Philadelphia

Cancer Specialists of Tidewater, Chesapeake

Cancer Centre of Southeastern Ontario, Kingston

Hospital Charles Lemoyne, Greenfield Park

Jewish General Hospital, Montreal

Chelyabinsk Regional Oncology Dispensary, Chelyabinsk

Blokhin Cancer Research Center (Dept. of Chemotherapy), Moscow

Blokhin Cancer Research Center (Dept. of Clinical Pharmacology and Chemotherapy), Moscow

Central Clinical Hospital, Moscow

Moscow Oncology Hospital #62, Moscow

St. Petersburg City Oncology Center, Saint Petersburg

Samara Regional Oncology Center, Samara

Regional Oncology Dispensary, Yaroslavl

Clinic for Pulmonary Diseases, Military Medical Academy, Belgrade

Clinic for Pulmonary Diseases, Belgrade

Institute for Oncology and Radiology of Serbia, Belgrade

Institute for Pulmonary Diseases of Vojvodina, Kamenitz

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pharmacyclics LLC.

INDUSTRY